Oxaliplatin-combination treatment has been adopted as a standard adjuvant treatment for high-risk stage II and stage III colorectal cancer. Cerebral venous sinus thrombosis (CVST) is a serious adverse event related to this combination treatment. The benefits of this combination treatment outweigh the risks, yet some physicians are reluctant to resume the treatment after the clot has resolved. The authors reported a case of CVST, and the success in resolving this situation with the use of a secondary prophylaxis, a low-molecular weight heparin.

Keywords: Oxaliplatin; Central venous sinus thrombosis; Chemotherapy-induced VTE

DOI: doi.org/10.35755/jmedassocthai.2021.12.12675

Received 15 March 2021 | Revised 18 June 2021 | Accepted 23 June 2021